Huakang Biomedical Holdings Co Ltd
Company Profile
Business description
Huakang Biomedical Holdings Co Ltd is engaged in the research, development, manufacture, marketing, and sale of in-vitro diagnostic reagents and auxiliary reproductive supplies and equipment in China. Its products include Male fertility IVD reagents; Parasite antibody detection reagents, EBV antibody detection reagents, and Auxiliary reproductive supplies and equipment. The group has also diversified its business to vitamins and supplements products for the markets in the PRC, Hong Kong, and Canada. The company derives maximum revenue from PRC.
Contact
No.16 Yinkui Road
1-3 floor and 5th floor, Building D, Shenzhen Junxuan
Kui Xin Community, Kui Chong Office
Dapeng New District
Shenzhen
CHNT: +86 75533853878
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
98
Stocks News & Analysis
stocks
Westpac earnings: Tech overhaul is costly but not hurting lending and deposit growth
stocks
Berkshire Hathaway earnings: Cash balances hit $358 billion on mostly solid results across the firm
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,099.70 | 74.30 | -0.81% |
| CAC 40 | 8,109.79 | 11.28 | -0.14% |
| DAX 40 | 24,132.41 | 174.11 | 0.73% |
| Dow JONES (US) | 47,336.68 | 226.19 | -0.48% |
| FTSE 100 | 9,701.37 | 15.88 | -0.16% |
| HKSE | 26,216.89 | 58.53 | 0.22% |
| NASDAQ | 23,834.72 | 109.77 | 0.46% |
| Nikkei 225 | 52,361.14 | 50.20 | -0.10% |
| NZX 50 Index | 13,601.17 | 44.87 | 0.33% |
| S&P 500 | 6,851.97 | 11.77 | 0.17% |
| S&P/ASX 200 | 8,815.50 | 67.20 | -0.76% |
| SSE Composite Index | 3,969.33 | 7.19 | -0.18% |